Navigation Links
PAREXEL International To Present At Oppenheimer Healthcare Conference
Date:12/5/2012

BOSTON, Dec. 5, 2012 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL) announced today that it will be presenting at the Oppenheimer Healthcare Conference in New York.  Josef von Rickenbach, Chairman and Chief Executive Officer, will be making a presentation on PAREXEL at 2:10 p.m.  EST on Thursday, December 13, 2012.

A live webcast of the presentation will be available through the "Investors" section of PAREXEL's website at www.parexel.com in the Upcoming Events portion of the main page, and a replay of the presentation will be available on the website until March 13, 2013.

About PAREXEL International

PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 70 locations throughout 51 countries around the world, and has approximately 13,330 employees. For more information about PAREXEL International visit www.parexel.com.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.

Contact:                                                                                                                                                                 Jill Baker, Corporate Vice President, Investor Relations
PAREXEL International
Tel: +781-434-4118     
Email: Jill.Baker@parexel.com


'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. PAREXEL International To Present At Lazard Capital Healthcare Conference And Jefferies Global Healthcare Conference
2. PAREXEL and Salem State University Launch Clinical Trial Management Graduate Program
3. PAREXEL International to Present at Robert Baird Healthcare Conference
4. PAREXEL Strengthens Outcomes Research Capabilities To Help Biopharma Meet Commercialization Goals
5. PAREXEL Launches The PAREXEL BioPharm Unit To Meet The Critical Development Goals Of Small And Mid-Sized Biopharmaceutical Companies
6. PAREXEL And Korea Drug Development Fund Announce Alliance To Accelerate Global Drug Development And Commercialization
7. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2012 Earnings Release and Conference Call
8. PAREXEL International To Present At NASDAQ OMX Investor Conference
9. PAREXEL International Issues Earnings Guidance In Conjunction With Investor Day
10. PAREXEL Chairman And CEO To Ring The Bell At The NASDAQ Stock Market Opening
11. Parexel Invites Public To Listen To Live Webcast Of Its Investor Day May 31, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., ... vaccine design, and immune-engineering today announced the launch ... the development of personalized therapeutic cancer vaccines. EpiVax ... provided exclusive access to enabling technologies to the ... MBA will lead EpiVax Oncology as Chief Executive ...
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
Breaking Medicine Technology:
(Date:9/26/2017)... ... 2017 , ... “Childhood Memories of a Virginia Wanderer”: an entertaining look ... relive their own youth. “Childhood Memories of a Virginia Wanderer” is the creation of ... nine years. He received his BS from Idaho State University in Adult Education, ...
(Date:9/26/2017)... ... , ... “The Tour Guide”: is the life story of the author and the exciting times ... Alexander Stark, is an adventure tour guide and the subject of the book. , ... confront fifteen shocked faces. I played it off as a part of the adventure tour, ...
(Date:9/26/2017)... ... , ... “The Great Creator Saves Boobie and Ceebie”: a tool families can use to teach ... the creation of published author, G.S. White, a devoted follower of Jesus Chris who is ... , “This book is not only for children but also to glorified God in everything ...
(Date:9/25/2017)... CA (PRWEB) , ... September 26, 2017 , ... Your ... agent in February 2017 and began fulfilling a life-long wish of owner Stacy Boyle ... “I was a recipient of help when I was in high school,” said Ms. ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... and only fully programmable fall detection smart watch. VitalBand provides elite level ... contacts as you want so help arrives quickly. Plus, it’s a fully ...
Breaking Medicine News(10 mins):